Butterfly glioblastomas: a retrospective review and qualitative assessment of outcomes

Abstract  

To address a paucity of literature and treatment guidelines regarding the management of butterfly glioblastomas, we performed a ten year retrospective analysis of data from twenty-three consecutive patients treated for this disease at a single institution. Clinical characteristics and outcomes were assessed. Median age was 59 years; 52 % were female; median preoperative Karnofsky performance score (KPS) was 80. Twelve patients underwent biopsy and eleven underwent surgical decompression. The median tumor volume for the biopsy group was 60.6 cm³ and for the surgically decompressed group 40.5 cm³. In the biopsy group, five patients received adjuvant therapy but one died prior to its completion; two died prior to the initiation of adjuvant therapy and five were lost to follow up. In the surgical decompression group, seven patients received adjuvant therapy, one died prior to the initiation of adjuvant therapy, two were treated with palliative measures only, and one was lost to follow up. Kaplan–Meier estimates of overall median post surgical-survival of the whole group was 180 days, the biopsy group 48 days, and the surgically decompressed group 265 days (p = 0.14). Our results show that there was a higher median survival in the surgically decompressed group; but a direct correlation could not be established, and that the median KPS did not improve in either group after treatment. A larger multicenter review is required to quantitatively assess the factors, including tumor biomarkers that are associated with patient outcome.

• Content Type Journal Article
• Category Clinical Study
• Pages 1-9
• DOI 10.1007/s11060-012-0926-0
• Authors
  • Kristine Dziurzynski, Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Unit 442, Houston, TX 77030, USA
  • David Blas-Boria, Neurology Section, Department of Internal Medicine, University of Puerto Rico, San Juan, PR, USA
  • Dima Suki, Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Unit 442, Houston, TX 77030, USA
  • Daniel P. Cahill, Department of Neurosurgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
  • Sujit S. Prabhu, Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Unit 442, Houston, TX 77030, USA
  • Vinay Puduvalli, Department of Neurooncology, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Unit 442, Houston, TX, USA
  • Nicholas Levine, Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Unit 442, Houston, TX 77030, USA

• Journal Journal of Neuro-Oncology
• Online ISSN 1573-7373
• Print ISSN 0167-594X

http://www.springerlink.com/content/r87649648k721250/

Sent with MobileRSS for iPhone

Júlio Leonardo B. Pereira

http://lattes.cnpq.br/7687651239699170

http://www.neurocirurgiabr.com